

Ghrelin: A Review

Surabhi R Jain

BDS Student, Saveetha Dental College

Abstract:

Ghrelin is a neuroendocrine hormone secreted mainly by P/D1 cells of gastric fundus. It may also be expressed in the pancreatic islets, hypothalamus, pituitary and several tissues in the periphery. Ghrelin is made of 28 amino acids and exists in two major forms: n-octanoyl modified ghrelin and des-acyl ghrelin. It acts as a ligand for the growth hormone (GH) secretagogue receptor and plays a major role in appetite stimulation. Apart from influencing the release of growth hormone from pituitary, it also functions on gastrointestinal system, cardiovascular system, energy balance and metabolism.

Key Words: Ghrelin, Growth hormone, appetite, food intake.

INTRODUCTION:

Ghrelin, a ligand for the growth hormone secretagogue (GHS) receptor (GHSR) [1], was discovered in 1999 after a research done on rat stomach produced an extract that activated the GHSR [1]. Ever since stomach has been recognized as the richest source of ghrelin produced chiefly by endocrine cells known as P/D1 cells [2, 3]. The name ghrelin come from the root word "ghre", which means "grow" in Proto-Indi-European language. Ghrelin stimulates the secretion of GH, increases food intake and in turn produces gain in weight [4, 5]. Apart from its effect on GH, it has various important biological actions like regulation of cardiovascular functions [6, 7], stimulating gastric acid motility and secretion [8], modulating cell proliferation and survival [9], energy balance and metabolism. It is also associated with regulation of blood glucose, obesity and sleep wake cycle.

GHRELIN AND HORMONAL SECRETIONS:

Growth Hormone (GH) secretion by anterior pituitary is regulated by Growth Hormone Releasing Hormone (GHRH) and somatostatin which stimulate and increase its secretions respectively. Studies on artificial GHS have shown that ghrelin acts synergistically with GHRH to stimulate GH secretion from pituitary cells [1,10]. Ghrelin induced GH secretions in humans is much stronger than GHRH [10]. Studies conducted on anaesthetized rats have shown that both intravenous [11] and intracerebroventricular [1] administration of ghrelin increased rat plasma GH concentration, with the latter being more potent route. In high doses, ghrelin stimulates the secretion of prolactin, corticotropin, and cortisol.

EFFECT OF GHRELIN ON CARDIOVASCULAR FUNCTION:

The evidence for cardiovascular function of ghrelin has been found: expression of mRNA encoding both ghrelin and its receptors has been observed in the heart and aorta [12,13]. Also the intravenous injection of ghrelin in human volunteers induces a decrease in blood pressure [13]. In vitro studies revealed the inhibition of apoptosis of cardiomyocytes and endothelial cells by increased ghrelin levels [9]. An intravenous bolus of human ghrelin decreased the mean arterial pressure without changing the heart rate [13,14]. In addition ghrelin also increased

the cardiac index and stroke volume indices. Ghrelin treated rats with chronic heart failure (CHF) showed an increase in cardiac output, stroke volume and left ventricular $\Delta P/\Delta t$ [max] compared with afflicted, but placebo-treated controls [21]. Elevated plasma ghrelin levels have also been found in humans suffering from CHF associated with cachexia [16]. Ghrelin expression has also been found in human placenta and some fetal tissues suggesting its role in cardiovascular adaptation during pregnancy [17].

EFFECT OF GHRELIN ON GASTROINTESTINAL FUNCTIONS:

Ghrelin is a gastric peptide released by oxyntic cells in stomach [1]. The plasma levels of ghrelin rise prior to intake of food and decline rapidly when food is consumed [18]. Exogenous administration of ghrelin also increases food intake [19] and it plays a role in meal initiation. The number of meals is said to be majorly effected in response to ghrelin administration [20]. Central and peripheral ghrelin administration results in increased expression of the orexigenic peptides NPY and AgRP within the arcuate nucleus of hypothalamus [21,22]. The intravenous administration of ghrelin dose-dependently increases gastric acid secretion and stimulates gastric motility [23,24]. The maximum response to ghrelin in terms of gastric acid secretion is almost as high as that shown by subcutaneous treatment with histamine [3mg/kg]. These responses to ghrelin were abolished by pre-treatment with either atropine or bilateral cervical vagotomy, but not by a histamine H₂-receptor antagonist. Intracerebroventricular administration of ghrelin was shown to induce c-fos expression in the nucleus of solitary tract and dorsomotor nucleus of vagus nerve.

EFFECT OF GHRELIN IN FOOD INTAKE:

Ghrelin is known to transport hunger signals from periphery to the central nervous system. Research has shown that intravenous and subcutaneous injections of ghrelin in rodents resulted in increase in their food intake and thus increase in their body weight gain and decrease in fat utilization [5]. Immunohistochemical analyses indicate that ghrelin containing neurons are found in the arcuate nucleus (ARC) of hypothalamus [1]. This region of

hypothalamus is involved in appetite regulation. In fact, chronic intracerebroventricular injection of ghrelin increases cumulative food intake and decreases energy expenditure, resulting in body weight gain [5,19,25,26,27]. This orexigenic effect of hypothalamic ghrelin is regulated through a neuronal network. To stimulate the release of orexigenic peptides in ARC, ghrelin containing neurons send efferent fibers onto NPY- and AgRP-expressing neurons. It also sends efferent fibres to POMC neurons to suppress the release of anorexigenic peptides. Studies indicate that intracerebroventricular injection of ghrelin induces Fos expression in NPY-expressing neurons and increases the amount of NPY mRNA in the ARC [5,25,26]. It also increases the AgRP mRNA level in the hypothalamus. The ARC is also a target of leptin, which is an appetite-suppressing hormone produced in adipose tissues [28,29]. Leptin directly inhibits the appetite stimulating effects of NPY and AgRP. Hypothalamic ghrelin augments NPY gene expression and blocked leptin-induced feeding reduction. Thus, ghrelin and leptin have competitive interactions and ghrelin is functionally a natural antagonist to leptin.

Ghrelin is the first identified circulating hormone that promotes feeding following peripheral administration. The rate at which peripheral ghrelin passes the blood-brain barrier has shown to be very low and thus peripheral ghrelin must activate the appropriate hypothalamic regions via an indirect pathway. The presence of ghrelin receptors on vagal afferent neurons in the rat nodose ganglion suggests that ghrelin signals from the stomach are transmitted to the brain via the vagus nerve [30,31]. Moreover, ghrelin activates the vagus system by inducing c-Fos in the dorsomotor nucleus of the vagus [32]. As noted above, vagotomy actually inhibits the ability of ghrelin to stimulate food intake [30]. A similar effect was also observed when capsaicin was applied to vagus nerve terminals to induce sensory denervation. Fasting-induced elevation of plasma ghrelin is completely abolished by subdiaphragmatic vagotomy or atropine treatment [33]. In summary, ghrelin is secreted primarily from stomach in response to hunger and starvation, circulates in the blood, and serves as a peripheral signal, conveying the central nervous system (via vagus nerve) to stimulate feeding.

Meals and ghrelin:

Ghrelin is secreted in a pulsatile manner, peaking at 2000 h, rising before meals and returning to basal levels after food ingestion. Plasma ghrelin levels increase by about two folds immediately before each meal and fall to minimum levels within 1 h after eating [18, 34]. The clear preprandial rise and postprandial fall in plasma ghrelin levels support the hypothesis that ghrelin is an initiation signal for meal consumption. Research studies have shown preprandial increase in ghrelin levels in humans that initiated meals voluntarily without any time- and food-related cues. Furthermore, the postprandial suppression of plasma ghrelin level is proportional to the ingested caloric load [35], further reinforcing that ghrelin is a hunger signal.

Ghrelin gene expression and appetite:

The gene expression of ghrelin in the stomach is increased by fasting and decreased by administration of leptin and interleukin (IL)-1 [36,37,38]. It promotes a positive energy balance by increasing food intake, decreasing energy expenditure and blocking IL-1-induced anorexia. All these facts suggest a possible clinical use of ghrelin for pathological anorexia that occurs as a side effect of some drugs and surgical operations and as a symptom of cancer and AIDS.

Ghrelin and gastric bypass surgery:

Obesity is a global epidemic caused by chronic impaired balance between energy supply and its expenditure. It leads to gathering of excessive fat tissues in the body. As ghrelin is functionally associated with energy homeostasis, it is intimately related to obesity. Gastric bypass operations are often performed to treat severe obesity [39,40]. This procedure reduces the space for food in gastric lumen and hence reduces the total calorie intake. Statistics show that in the United States, a total of 40,000 people are estimated to have been treated with a gastric bypass in 2000, and 75,000 in 2001. However, the exact mechanism of action of this operation is still unclear.

Recent research has revealed that ghrelin may contribute to the body weight reduction that occurs post gastric bypass. The patients receiving the procedure and having successful weight loss were examined for their plasma ghrelin levels [41,42,43]. It was found that total ghrelin secretion was reduced by up to 77% compared with normal-weight control groups and by up to 72% compared with matched obese groups [41]. Moreover, the normal meal-related fluctuations and diurnal rhythm of ghrelin level were absent in these patients. The mean plasma ghrelin concentration decreased significantly after gastric bypass surgery and may have been responsible for their lack of hyperphagia and contributed to their weight loss. The mechanism for decreasing plasma ghrelin level in gastric bypass patients is still unknown and one hypothesis is that direct contact between gastric mucosa and food is important for the production and secretion of ghrelin [44].

OTHER FUNCTIONS OF GHRELIN:

Studies have suggested that ghrelin leads to increased gastrointestinal motility and (possibly) increased gastric acid secretion, which may play a physiological role in preparing the gastrointestinal tract to process food. [24,36,45-48]. In terms of gastric acid secretion, the maximum response to ghrelin is almost as high as that elicited by subcutaneous treatment with histamine (3 mg/kg). Pretreatment with either atropine or bilateral cervical vagotomy, abolished these responses to ghrelin but not by a histamine H₂-receptor antagonist.

There are many evidences on the regulation of insulin secretion by ghrelin [49-52]. It was reported by Date et al. that ghrelin stimulates insulin release in the presence of high levels of glucose (8.3 mM/l) that could independently cause insulin release from cultured islet cells [49]. In contrast to this, ghrelin had no effect on insulin release

in the context of a basal level of glucose (2.8 mM/l). Ghrelin has also shown to reduce insulin secretion and induce hyperglycemia in humans [53]. The role played by ghrelin on insulin secretion is still a matter of debate among researchers and further research in the field is required.

After the discovery of ghrelin, it was realized that the stomach plays a major role not only for digestive functions but also for the regulation of energy metabolism and secretion of GH.

In addition to the appetite-related neuronal pathways activated by ghrelin, ghrelin receptors are present in many areas of brain that can affect mood and emotions, and, indeed, it was found that ghrelin may interfere with the regulation of the stress response, mood, and anxiety.

Ghrelin and its agonists may also modulate immune functions by enhancing immune cell proliferation and inhibiting the secretion of proinflammatory cytokines from immune cells [54-56].

The novel octanoylated structure of ghrelin represents a new finding in biochemistry. The newly identified enzyme that catalyzes the acyl-modification of ghrelin, GOAT, provides an important clue in the secretory machinery of ghrelin. The mechanism of ghrelin synthesis still remains unclear and hopefully will be elucidated by future research.

CONCLUSION:

A critical review of the newly discovered chemical messenger ghrelin and its numerous actions is provided

REFERENCES:

- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a GH-releasing acylated peptide from stomach. *Nature* 402:656 – 660, 1999
- Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. *J Clin Endocrinol Metab* 2001; 86:4753.
- Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. *Endocrinology* 2000; 141:4255.
- Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. *J Clin Endocrinol Metab* 2000; 85:4908.
- Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. *Nature* 2001; 409:194.
- Shimizu Y, Nagaya N, Teranishi Y, Imazu M, Yamamoto H, Shokawa T, Kangawa K, Kohno N, Yoshizumi M. Ghrelin improves endothelial dysfunction through growth hormone independent mechanisms in rats. *Biochem Biophys Res Commun*. 2003;310(3):830–835. [PubMed]
- Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, Ueno K, Kitakaze M, Miyatake K, Kangawa K. Effects of Ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. *Circulation*. 2004;110(24):3674–3679. [PubMed]
- Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, Hosoda H, Kojima M, Kangawa K. Ghrelin stimulates gastric acid secretion and motility in rats. *Biochem Biophys Res Commun*. 2000;276(3):905–908. [PubMed]
- Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, Broglio F, Papotti M, Surico N, Bussolino F, Isgaard J, Deghenghi R, Sinigaglia F, Prat M, Muccioli G, Ghigo E, Graziani A. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. *J Cell Biol*. 2002;159(6):1029–1037. [PMC free article] [PubMed]
- Arvat E, Di Vito L, Broglio F, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, and Ghigo E. Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)- receptor ligand, strongly stimulates Gh secretion in humans. *J Endocrinol Invest* 23: 493–495, 2000
- Date Y, Murakami N, Kojima M, Kuroiwa T, Matsukura S, Kangawa K, and Nakazato M. Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. *Biochem Biophys Res Commun* 275: 477–480, 2000.
- Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB, and Korbonits M. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. *J Clin Endocrinol Metab* 87: 2988, 2002
- Nagaya N and Kangawa K. Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. *Curr Opin Pharmacol* 3: 146–151, 2003
- Nagaya N, Miyatake K, Uematsu M, Oya H, Shimizu W, Hosoda H, Kojima M, Nakanishi N, Mori H and Kanagawa K. Hemodynamic, renal and hormonal effects of ghrelin infusion in patients with chronic heart failure. *J Clin Endocrinol Metab* 86:5854–5859, 2001
- Nagaya N and Kangawa K. Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. *Curr Opin Pharmacol* 3: 146–151, 2003.
- Nagaya N, Uematsu M, Kojima M, et al: Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. *Circulation* 104: 2034–2038, 2001.
- Makino Y, Hosoda H, Shibata K, Makino I, Kojima M, Kangawa K and Kawarabayashi T: Alteration of plasma ghrelin levels associated with the blood pressure in pregnancy. *Hypertension* 39: 781–784, 2002.
- Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. *Diabetes*. 2001;50:1714–1719. [PubMed]
- Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. *Nature*. 2000;407:908–913. [PubMed]
- Faulconbridge LF, Cummings DE, Kaplan JM, Grill HJ. Hyperphagic effects of brainstem ghrelin administration. *Diabetes*. 2003;52:2260–2265. [PubMed]
- Seoane LM, Lopez M, Tovar S, Casanueva FF, Senaris R, Dieguez C. Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. *Endocrinology*. 2003;144:544–551. [PubMed]
- Kinzig KP, Scott KA, Hyun J, Bi S, Moran TH. Lateral ventricular ghrelin and fourth ventricular ghrelin induce similar increases in food intake and patterns of hypothalamic gene expression. *Am J Physiol Regul Integr Comp Physiol*. 2006;290:R1565–1569. [PubMed]
- Dornonville De La Cour C, Lindstrom E, Norlen P, and Hakanson R. Ghrelin stimulates gastric emptying but is without effect on acid secretion and gastric endocrine cells. *Regul Pept* 120:23–32, 2004.
- Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, Hosoda H, Kojima M, and Kangawa K. Ghrelin stimulates gastric acid secretion and motility in rats. *Biochem Biophys Res Commun* 276: 905–908, 2000.
- Kamegai, J., Tamura, H., Shimizu, T., Ishii, S., Sugihara, H., and Wakabayashi, I. (2001) Chronic Central Infusion of Ghrelin Increases Hypothalamic Neuropeptide Y and Agouti-Related Protein Mrna Levels and Body Weight in Rats *Diabetes* 50 5050 50, 2438-2443
- Shintani, M., Ogawa, Y., Ebihara, K., Aizawa-Abe, M., Miyanaga, F., Takaya, K., Hayashi, T., Inoue, G., Hosoda, K., Kojima, M., Kangawa, K., and Nakao, K. (2001) Ghrelin, an Endogenous Growth Hormone Secretagogue, Is a Novel Orexigenic Peptide That Antagonizes Leptin Action through the Activation of Hypothalamic Neuropeptide Y/Y1 Receptor Pathway *Diabetes* 50 5050 50, 227-232
- Wren, A. M., Small, C. J., Abbott, C. R., Dhillo, W. S., Seal, L. J., Cohen, M. A., Batterham, R. L., Taheri, S., Stanley, S. A.,

- Ghatei, M. A., and Bloom, S. R. (2001) Ghrelin Causes Hyperphagia and Obesity in Rats *Diabetes* 50: 2540-2547
28. Flier, J. S. (2004) Obesity Wars: Molecular Progress Confronts an Expanding Epidemic *Cell* 116: 337-350
 29. Morton GJ and Schwartz MW. The NPY/AgRP neuron and energy homeostasis. *Int J Obesity Relat Metab Disord* 25(Suppl 5): S56-S62, 2001
 30. Date, Y., Murakami, N., Toshinai, K., Matsukura, S., Nijijima, A., Matsuo, H., Kangawa, K., and Nakazato, M. (2002) The Role of the Gastric Afferent Vagal Nerve in Ghrelin-Induced Feeding and Growth Hormone Secretion in Rats *Gastroenterology* 123: 1120-1128
 31. Zhang, W., Lin, T. R., Hu, Y., Fan, Y., Zhao, L., Stuenkel, E. L., and Mulholland, M. W. (2004) Ghrelin Stimulates Neurogenesis in the Dorsal Motor Nucleus of the Vagus *J Physiol* 559: 729-737
 32. Date Y, Nakazato M, Murakami N, Kojima M, Kangawa K, and Matsukura S. Ghrelin acts in the central nervous system to stimulate gastric acid secretion. *Biochem Biophys Res Commun* 280:904-907, 2001
 33. Williams, D. L., Grill, H. J., Cummings, D. E., and Kaplan, J. M. (2003) Vagotomy Dissociates Short- and Long-Term Controls of Circulating Ghrelin *Endocrinology* 144: 5184-5187
 34. Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, and Heiman ML. Circulating ghrelin levels are decreased in human obesity. *Diabetes* 50: 707-709, 2001
 35. Callahan HS, Cummings DE, Pepe MS, Breen PA, Matthys CC, and Weigle DS. Postprandial suppression of plasma ghrelin levels is proportional to ingested caloric load but does not predict intermeal interval in humans. *J Clin Endocrinol Metab* 89: 1319-1324, 2001
 36. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Nijijima A, Fujino MA, and Kasuga M. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. *Gastroenterology* 120: 337-345, 2001
 37. Kim MS, Yoon CY, Park KH, Shin CS, Park KS, Kim SY, Cho BY, and Lee HK. Changes in ghrelin and ghrelin receptor expression according to feeding status. *Neuroreport* 14: 1317-1320, 2003
 38. Toshinai K, Mondal MS, Nakazato M, Date Y, Murakami N, Kojima M, Kangawa K, and Matsukura S. Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. *Biochem Biophys Res Commun* 281: 1220-1225, 2001
 39. Fisher BL and Schauer P. Medical and surgical options in the treatment of severe obesity. *Am J Surg* 184(Suppl. 9S-16S), 2002.
 40. Fobi MA. Surgical treatment of obesity: a review. *J Natl Med Assoc* 96: 61-75, 2004.
 41. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, and Purnell JQ. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. *N Engl J Med* 346: 1623-1630, 2002.
 42. Geloneze B, Tambascia MA, Pilla VF, Geloneze SR, Repetto EM, and Pareja JC. Ghrelin: a gut-brain hormone: effect of gastric bypass surgery. *Obesity Surg* 13: 17-22, 2003
 43. Leonetti F, Silecchia G, Iacobellis G, Ribaldo MC, Zappaterreno A, Tiberti C, Iannucci CV, Perrotta N, Bacci V, Basso MS, Basso N, and Di Mario U. Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. *J Clin Endocrinol Metab* 88: 4227-4231, 2003.
 44. Adami GF, Cordera R, Andraghetti G, Camerini GB, Marinari GM, and Scopinaro N. Changes in serum ghrelin concentration following biliopancreatic diversion for obesity. *Obesity Res* 12: 684-687, 2004.
 45. Fujino K, Inui A, Asakawa A, Kihara N, Fujimura M, Fujimiya M. Ghrelin induces fasted motor activity of the gastrointestinal tract in conscious fed rats. *J Physiol*. 2003; 550: 227-240.
 46. Inui A, Asakawa A, Bowers CY, et al. Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. *FASEB J*. 2004; 18: 439-456.
 47. Trudel L, Bouin M, Tomasetto C, et al. Two new peptides to improve post-operative gastric ileus in dog. *Peptides*. 2003; 24: 531-534.
 48. Trudel L, Tomasetto C, Rio MC, et al. Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. *Am J Physiol Gastrointest Liver Physiol*. 2002; 282: G948-G952
 49. Date, Y., Nakazato, M., Hashiguchi, S., Dezaki, K., Mondal, M. S., Hosoda, H., Kojima, M., Kangawa, K., Arima, T., Matsuo, H., Yada, T., and Matsukura, S. (2002) Ghrelin Is Present in Pancreatic Alpha-Cells of Humans and Rats and Stimulates Insulin Secretion *Diabetes* 51: 124-129
 50. Adegate, E., and Ponery, A. S. (2002) Ghrelin Stimulates Insulin Secretion from the Pancreas of Normal and Diabetic Rats *J Neuroendocrinol* 14: 555-560
 51. Lee, H. M., Wang, G., Englander, E. W., Kojima, M., and Greeley, G. H., Jr. (2002) Ghrelin, a New Gastrointestinal Endocrine Peptide That Stimulates Insulin Secretion: Enteric Distribution, Ontogeny, Influence of Endocrine, and Dietary Manipulations *Endocrinology* 143: 185-190
 52. Reimer, M. K., Pacini, G., and Ahren, B. (2003) Dose-Dependent Inhibition by Ghrelin of Insulin Secretion in the Mouse *Endocrinology* 144: 916-921
 53. Broglio, F., Arvat, E., Benso, A., Gottero, C., Muccioli, G., Papotti, M., van der Lely, A. J., Deghenghi, R., and Ghigo, E. (2001) Ghrelin, a Natural Gh Secretagogue Produced by the Stomach, Induces Hyperglycemia and Reduces Insulin Secretion in Humans *J Clin Endocrinol Metab* 86: 5083-5086
 54. Koo GC, Huang C, Camacho R, et al. Immune enhancing effect of a growth hormone secretagogue. *J Immunol*. 2001; 166: 4195-4201.
 55. Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. *J Clin Invest*. 2004; 114: 57-66.
 56. Dixit VD, Taub DD. Ghrelin and immunity: a young player in an old field. *Exp Gerontol*. 2005; 40: 900-910.